Red X iconGreen tick iconYellow tick icon
Skip to main content Skip to side navigation

Current research

  • Utilisation of psychotropic medicines in older people in New Zealand: A pharmacoepidemiological approach
  • Preventative medicine use in older people
  • Real-world haemorrhagic rates for warfarin and dabigatran using population-level data
  • Discontinuation of statin in a population of older New Zealanders with limited life expectancy
  • Drug Burden Index and adverse outcomes at a population level
  • Population level estimation and validation of anticholinergic drug burden
  • Predictive validity of anticholinergic risk scales on adverse outcomes at a population level

Publications

  • Narayan SW, Nishtala PS. Evaluation of the National Minimum Dataset for neurological conditions in older adults. Journal of Geriatric Psychiatry and Neurology. 2017; 30 :331-336. [2.109] [ 2.109]
  • Narayan SW, Nishtala PS. Discontinuation of Preventive Medicines in Older People with Limited Life Expectancy: A Systematic Review. Drugs Aging. 2017 Aug 29. doi: 10.1007/s40266-017-0487-1[IF:2.838]
  • Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, Furu K, Garuoliené K, Hoffmann F, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, Litchfield M, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Pearson SA, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Skurtveit S, Verdoux H, Wang LJ, Yahni CZ, Bachmann CJ. International trends in antipsychotic use: A study in 16 countries, 2005-2014. European Journal of Neuropsychopharmacology. 2017; 36: 37-38. [IF: 4.369]
  • Scrase R, Nishtala PS, Abey R, David T, Hilmer S, Abernethy D, Connolly M, Schluter P, Jamieson H. The Drug Burden Index and its association with falls among older adults. The Australasian Journal on Ageing. 2017; 36: 37-38. [IF: 0.678]
  • Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, Coma Fusté A, Furu K, Garuoliené K, Hoffmann F, Hollingworth S, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Piovani D, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Siskind D, Skurtveit S, Verdoux H, Wang LJ, Zara Yahni C, Zoëga H, Taylor D. International trends in clozapine use: A study in 17 countries. Acta Psychiatrica Scandinavica.2017; 36 :37-51 [IF:6.128].
  • Salahudeen MS, Nishtala PS. An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice. Saudi Pharmaceutical Journal, 2017; 25: 165-175. [IF: 2.233].
  • Nishtala PS & Chyou TY. Zopiclone use and risk of fractures in older people: population based study. Journal of the American Medical Directors Association. Journal of the American Medical Directors Association, 2017; 18: 368 [IF:6.616].
  • Ailabouni N, Mangin D, Nishtala PS. Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT-polypharmacy) in residential aged care facilities. BMJ Open, 2017 Apr 16;7(4): e013800. [IF:2.271].
  • Nishtala PS, Ndukwe HC, Chyou TY, Salahudeen MS, Narayan SW. An overview of pharmacoepidemiology in New Zealand: medical databases, registries and research achievements. The New Zealand Medical Journal, 2017; 130: 52-61.
  • Ndukwe HC, Tordoff JM, Wang T, Nishtala PS. Geographic variation in psychotropic drug utilisation among older people in New Zealand. The Australasian Journal on Ageing. 2015. doi:10.1111.ajag.12298. [IF:0.678]
  • Ndukwe HC, Nishtala PS. Donepezil adherence, persistence and time-to-first discontinuation in three-year follow-up of older people. Dementia and Cognitive Disorders extra. 2015. doi:10.1159/000441894
  • Ndukwe HC, Nishtala PS.Temporal trends for donepezil utilization among older people.International Clinical Psychopharmacology. 2015. Nov 16. [IF:3.098]
  • Nishtala PS , Gnjidic D, Jamiesonc HC, Hanger HC, Kaluarachchi C, Hilmer HN. 'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand 'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand. international Journal of Cardiology. 2016. 746-752. http://authors.elsevier.com/a/1S3OIc5r~7e3V.(click link to access article). [IF:4.036]
  • Narayan SW, Tordoff JM, Nishtala PS. Temporal trends in the utilisation of preventive medicines by older people: A 9-year population-based study. Archives of Gerontology and Geriatrics. 2015 Oct 26. [IF: 1.853]
  • Nishtala PS, Oh Sekbong, Kim Daniel, Chun Natalie, Kamis Siti Fatimah binti. Analgesic medicine utilization in older people in New Zealand from 2005 to 2013. Drugs-Real World Outcomes, 2015, 2:177-185
  • Narayan SW, Nishtala PS. Prevalence of potentially inappropriate medicine use in older New Zealanders: a population-level study using the updated 2012 Beers criteria. Journal of Evaluation in Clinical Practice, 2015; 21: 633-641. [IF: 1.834]
  • Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. Journal of American Geriatric Society, 2015; 63:85-90. [IF: 4.572]
  • Narayan S W. & Nishtala P S. Associations of potentially inappropriate medicine use with fall-related hospitalisations and primary care visits in older New Zealanders: A population-level study using the updated 2012 Beers Criteria. Drugs-Real World Outcomes, 2015, 2:137-141
  • Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatrics, 2015; 15:31 [IF: 1.680]
  • Nishtala PS, Soo L. Proton pump inhibitors utilisation in older people in New Zealand from 2005 to 2013. Internal Medicine Journal, 2015; 45:624-9 [IF: 1.644]
  • Nishtala PS, Salahudeen MS. Temporal Trends in Polypharmacy and Hyperpolypharmacy in Older New Zealanders over a 9-Year Period: 2005-2013. Gerontology, 2015; 61:195-2 [IF: 3.059]
  • Ndukwe HC, Tordoff JM, Wang T, Nishtala PS. Psychotropic medicine utilization in older people in New Zealand from 2005 to 2013. Drugs Aging, 2014; 31:755-768. [IF: 2.646]
  • Nishtala PS, Narayan SW, Wang T et al. Associations of drug burden index with falls, general practitioner visits, and mortality in older people. Pharmacoepidemiology and Drug Safety, 2014; 23:753-8 [IF: 2.897]
  • Salahudeen MS, Duffull SB, Nishtala PS. Impact of anticholinergic discontinuation on cognitive outcomes in older people: a systematic review. Drugs Aging, 2014; 31:185-192. [IF: 2.646]
  • Narayan SW, Hilmer SN, Horsburgh S, Nishtala PS. Anticholinergic component of the Drug Burden Index and the Anticholinergic Drug Scale as measures of Anticholinergic exposure in older people in New Zealand: A Population-Level study Drugs Aging, 2013; 30:927-34 [IF: 2.671]

Presentations

Back to top